Indication

As monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL), after two or more lines of systemic therapy.

Medicine details

Medicine name:
glofitamab (Columvi)
SMC ID:
SMC2614
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
10 June 2024
SMC meeting date:
07 May 2024
Patient group submission deadline:
TBC